Omeros (NASDAQ:OMER) Earns Buy Rating from D. Boral Capital

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $36.00 price target on the biopharmaceutical company's stock.

Several other research firms have also recently commented on OMER. StockNews.com cut shares of Omeros from a "hold" rating to a "sell" rating in a report on Wednesday, April 9th. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $22.50.

Omeros Trading Down 18.7%

NASDAQ OMER traded down $0.74 during trading on Tuesday, reaching $3.21. 3,001,035 shares of the company's stock were exchanged, compared to its average volume of 648,837. Omeros has a fifty-two week low of $2.97 and a fifty-two week high of $13.60. The company's fifty day simple moving average is $7.06 and its 200-day simple moving average is $8.14. The firm has a market capitalization of $187.16 million, a PE ratio of -1.39 and a beta of 2.42.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05). Equities analysts forecast that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Barclays PLC boosted its holdings in Omeros by 121.3% in the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company's stock worth $376,000 after purchasing an additional 51,873 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Omeros in the fourth quarter worth about $124,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Omeros by 12.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company's stock worth $392,000 after acquiring an additional 4,401 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Omeros during the 4th quarter valued at about $46,000. Finally, Cerity Partners LLC increased its holdings in shares of Omeros by 9.9% during the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock valued at $286,000 after acquiring an additional 2,600 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.